{"id":"NCT02576509","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma","officialTitle":"A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-07","primaryCompletion":"2019-05-30","completion":"2024-02-07","firstPosted":"2015-10-15","resultsPosted":"2020-06-26","lastUpdate":"2025-02-17"},"enrollment":743,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"DRUG","name":"Nivolumab","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"Nivolumab","type":"EXPERIMENTAL"},{"label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"time from the date of randomization to the date of death due to any cause, assessed up to June 2019 (approximately 41 months)","effectByArm":[{"arm":"Nivolumab 240 mg","deltaMin":16.39,"sd":null},{"arm":"Sorafenib 400 mg","deltaMin":14.69,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0752"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":138,"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","France","Germany","Hong Kong","Israel","Italy","Japan","Poland","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["36852452","36111952","35101942","34914889"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":216,"n":367},"commonTop":["Diarrhoea","Fatigue","Decreased appetite","Palmar-plantar erythrodysaesthesia syndrome","Abdominal pain"]}}